Cargando…
Suppression of lupus nephritis and skin lesions in MRL/lpr mice by administration of the topoisomerase I inhibitor irinotecan
BACKGROUND: Since the precise mechanism for the pathogenesis of systemic lupus erythematosus (SLE) is unknown, no targeted therapies in addition to immunosuppression are available so far. We recently demonstrated that administration of the topoisomerase I (topo I) inhibitor irinotecan at extremely l...
Autores principales: | Keil, Andreas, Hall, Sean R., Körner, Meike, Herrmann, Martin, Schmid, Ralph A., Frese, Steffen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5075215/ https://www.ncbi.nlm.nih.gov/pubmed/27770825 http://dx.doi.org/10.1186/s13075-016-1144-5 |
Ejemplares similares
-
ALW peptide ameliorates lupus nephritis in MRL/lpr mice
por: Wang, Huixia, et al.
Publicado: (2019) -
Reduction of lupus nephritis in MRL/lpr mice by a bacterial superantigen treatment
Publicado: (1991) -
The new complement inhibitor CRIg/FH ameliorates lupus nephritis in lupus-prone MRL/lpr mice
por: Shi, Yu, et al.
Publicado: (2019) -
Investigating the Mechanisms of Jieduquyuziyin Prescription Improves Lupus Nephritis and Fibrosis via FXR in MRL/lpr Mice
por: Liu, Jingqun, et al.
Publicado: (2022) -
Urine SERPINC1/ORM1 as biomarkers for early detection of lupus nephritis in MRL-lpr mice
por: Kim, Young-Eun, et al.
Publicado: (2023)